Healthcare Professionals

  • Email
  • Help

Information for you

On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events.

You can contribute to the Agency’s work by responding to public consultations

Learn more about how Healthcare Professionals are actively involved in the work of the Agency.

Featured information

  • Patients’ and healthcare professionals’ meeting

    The joint meeting of patients’ and healthcare professionals’ working parties took place in March. Participants discussed interaction with patients in 2015, measuring the impact of pharmacovigilance activities, the ICH guideline on good clinical practice and access to EudraVigilance data. EMA will publish the meeting minutes and presentations.

  • information on medicines

    Communication and information on medicines

    Patients and healthcare professionals took part in a session on communication and information on medicines, focusing on how information on medicines is produced and used. Participants considered survey results to identify the current landscape, then discussed opportunities for improvement and future research areas. EMA expects to publish a report on the session.

  • healthcare_professional

    Resources for healthcare professionals

    EMA updated its online content for healthcare professionals and added Resources for healthcare professionals. This page provides links to relevant content on themes including summary of product characteristics, medication errors and relevant workshops. It also includes a series of short videos called EMA Basics. These cover the role of EMA, the centralised procedure and how EMA works with healthcare professionals. More videos will follow in 2016.

  • bacteria

    Antimicrobial resistance

    Antimicrobial resistance is a growing problem in humans and in animals. EMA is concerned about the development of antimicrobial resistance, particularly resistance to antibiotics. Read more about EMA’s activities in relation to antimicrobial resistance.

News for healthcare professionals

Events of interest

  • 30/06/2016

    EMA

    Workshop on single-arm trials (SAT) in oncology

    Single-arm trials (SATs) have led to regulatory approval of oncology products in case of dramatic activity in well-defined populations with high unmet medical need. Further, when randomized-controlled trials are not possible, SATs augmented with statistical approaches may become the standard basis of evidence of efficacy for new applications. However, what constitutes dramatic activity and high unmet medical need is often debated and there is no regulatory guidance on cancer drug development in these situations and how to manage the remaining uncertainties optimally. This workshop will debate the experience gained with these types of approvals, the strengths and weaknesses of different approaches, explore the views of different stakeholders and underlying principles, and will discuss the need and appropriateness for further regulatory guidance. ... Read more

  • 09/03/2016

    EMA

    Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins

    The workshop is held to discuss the draft Committee for Medicinal Products for Human Use/Biosimilar Medicinal Products Working Party (BMWP) guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Participants will include experts from the BMWP, the Biostatistics Working Party (BWP), other regulatory authorities and stakeholders who provided comments on the draft guideline as well as specifically invited interested parties. ... Read more

  • 07/06/2016

    EMA

    Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis

    In the frame of public consultation on the revision of the guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis, the European Medicines Agency is hosting a meeting to supplement the ongoing debate. ... Read more

  • 01/06/2016 - 02/06/2016

    EMA

    IMI ADAPT SMART, IMI GetReal and MIT NEW Drug Development ParadIGmS (NEWDIGS) “Adaptive Design Laboratory” workshop

    The format of this two-day workshop is based on the NEWDIGS ‘scenario design’ methodology which leverages case studies to facilitate open yet structured discussion among stakeholders from different sectors regarding scientific, regulatory and utilization issues; and how potential options for integrated evidence generation and use plans across the product life span might help resolve those issues. In this workshop, Day 1 will focus on a retrospective case and, in particular, explore options for how Real World Evidence might be used to bridge the efficacy to effectiveness gap. Day 2 will be a retrospective review of a product, exploring “what if” Adaptive Pathways had been available, what other scenarios might have emerged in terms of its development, licensing, and utilization. ... Read more

  • 02/06/2016 - 03/06/2016

    EMA

    2016 annual workshop of the European network of paediatric research (Enpr-EMA) at the European Medicines Agency

    The first day of the workshop is an open meeting to all stakeholders, including patient and parent organisations, network representatives, pharmaceutical industry staff responsible for paediatric studies and regulators. The main tocpics of the workshop this year will be the deliverables of the working groups and the implementation of the new Clinical Trial Regulation with a focus on ethics related issues. The second day is dedicated to members of Enpr-EMA and its coordinating group. ... Read more

  • See all Events of interest

Information for:

Find information for...

Medicines for elderly

ADR website spotlight

FAQ spotlight